how glp-1 improve insulin resistance GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous production and L-cell differentiation | Diabetology & Metabolic Syndrome The central and peripheral effects

doi:10.1016/j.regpep.2014.04.003 140

Diverse enzyme networks and endogenous metabolites inhibit lipid peroxidation by disrupting its onset or progression

GLP-1 receptor agonists as a class share similar mechanisms and therefore comparable digestive effects, though individual medications show some distinctions

Some strategies focus on supporting the bodys ability to maintain glutathione by providing building blocks

The digestive symptoms experienced during GLP-1 therapy result from altered gastrointestinal motility and delayed gastric emptying rather than enzyme deficiency

Kaufman believes that by reducing systemic inflammation, the GLP-1 agonists are getting at one of the root causes of these diseases